Real World Outcomes of Metastatic Rhabdomyosarcoma in Children Treated With a Multimodal Protocol: A Single Center Experience
Authors:
- Kruti ShahKSKruti Shah
- Badira Cheriyalinkal ParambilBPBadira Cheriyalinkal Parambil
- Maya PrasadMPMaya Prasad
- Siddhartha LaskarSLSiddhartha Laskar
- Nehal KhannaNKNehal Khanna
- Jifmi J. ManjaliJMJifmi J. Manjali
- Sajid QureshiSQSajid Qureshi
- Mukta RamadwarMRMukta Ramadwar
- Poonam PanjwaniPPPoonam Panjwani
- Vasundhara PatilVPVasundhara Patil
- Akshay BahetiABAkshay Baheti
- 4 August 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (7) , 313-322
Abstract
Background and Aims: Metastatic rhabdomyosarcoma (RMS) at diagnosis has poor outcomes. We audited these outcomes in children at a tertiary sarcoma unit. Methods: Children aged 15 years or younger with RMS at first diagnosis staged by FDG-PET CECT scan between January 2013 and December 2024 were retrospectively analyzed. Pulmonary, lymph node, and oligometastatic bone disease were treated with curative intent on a multimodal protocol comprising chemotherapy and local therapy to the primary and metastatic sites. Results: Of 126 patients, 19% had isolated pulmonary, 81% had extrapulmonary metastases, with bone marrow involvement in 3.1%. After neoadjuvant chemotherapy in 73 patients (treated with curative intent), 74% had complete response (CR), 19% partial response (PR), 4% stable disease, and 3% progression. Local therapy to the primary was given to 68 patients (radiotherapy: 70.5%, surgery+radiotherapy: 22.1%, surgery: 7.3%), and metastatic sites were treated in 61.8%. At a median follow-up of 11 months (IQR: 3.31, 20.8), 2-year EFS and OS probabilities were 30.2% (95% CI: 19.8-41.2) and 44.4% (95% CI: 32.5-55.6), respectively; survival did not differ by metastasis site. Complete response at primary (HR: 0.09, 95% CI: 0.30-0.29, P P =0.008), and bone marrow involvement (HR: 1.98, 95% CI: 1.01-3.91, P =0.050) affected EFS. Conclusions: Despite multimodal therapy, metastatic rhabdomyosarcoma continues to have poor outcomes. Tumor size ≥3.3 cm in oligometastatic disease and bone marrow involvement predicted poor prognosis, while complete primary site response after neoadjuvant chemotherapy was associated with improved survival.Keywords
This publication has 28 references indexed in Scilit:
- Prognosis of children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone marrow treated on Children's Oncology Group studiesPediatric Blood & Cancer, 2023
- Rhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology GroupPediatric Blood & Cancer, 2023
- Pediatric rhabdomyosarcoma with bone marrow metastasisPediatric Blood & Cancer, 2020
- Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology GroupCancer Medicine, 2019
- Local therapy to distant metastatic sites in stage IV rhabdomyosarcomaPediatric Blood & Cancer, 2017
- Pediatric rhabdomyosarcoma in India: A single-center experienceIndian Pediatrics, 2017
- Embryonal rhabdomyosarcoma with metastases confined to the lungs: Report from the CWS Study GroupPediatric Blood & Cancer, 2010
- Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975‐2005Cancer, 2009
- Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic typeCancer, 1995
- Prognostic significance of regional lymph node involvement in childhood extremity rhabdomyosarcomaMedical and Pediatric Oncology, 1990